Curasight announed positive readout from a preclinical study in aggressive brain cancer (glioblastoma), showing that uTREAT inhibited tumour growth. This takes the company closer to reaching the full potential of the theranostic platform where uTRACE and uTREAT work in combination offering diagnostics and treatment. Even though the development is at an early stage, we view this as supportive for the continued development of the treatment.

Link to the analysis